228 related articles for article (PubMed ID: 21207206)
1. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
Jacob MS; Tang WH
Curr Heart Fail Rep; 2011 Mar; 8(1):7-13. PubMed ID: 21207206
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Thohan V; Torre-Amione G; Koerner MM
Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
4. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.
Dhillon S
Drugs; 2013 Sep; 73(13):1451-62. PubMed ID: 23881669
[TBL] [Abstract][Full Text] [Related]
5. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
Zannad F; McMurray JJ; Drexler H; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Eur J Heart Fail; 2010 Jun; 12(6):617-22. PubMed ID: 20388647
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone antagonists in heart failure.
Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
10. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone antagonism and myocardial infarction: from animals to man and back.
Solomon SD; Pfeffer MA
J Am Coll Cardiol; 2003 Nov; 42(9):1674-6. PubMed ID: 14607458
[No Abstract] [Full Text] [Related]
13. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone antagonists in systolic heart failure.
Lindblad AJ; Allan GM
Can Fam Physician; 2014 Feb; 60(2):e104. PubMed ID: 24522687
[No Abstract] [Full Text] [Related]
15. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H;
Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642
[TBL] [Abstract][Full Text] [Related]
16. Role of a selective aldosterone blocker in mice with chronic heart failure.
Wang D; Liu YH; Yang XP; Rhaleb NE; Xu J; Peterson E; Rudolph AE; Carretero OA
J Card Fail; 2004 Feb; 10(1):67-73. PubMed ID: 14966777
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Girerd N; Collier T; Pocock S; Krum H; McMurray JJ; Swedberg K; Van Veldhuisen DJ; Vincent J; Pitt B; Zannad F
Eur Heart J; 2015 Sep; 36(34):2310-7. PubMed ID: 26093641
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
Nappi JM; Sieg A
Vasc Health Risk Manag; 2011; 7():353-63. PubMed ID: 21731887
[TBL] [Abstract][Full Text] [Related]
20. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Pitt B
J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
